Compounds for inflammation and immune-related uses

1. A method of treating organ transplant rejection, psoriasis, atopic dermatitis, chronic autoimmune urticaria, rheumatoid arthritis, hemolytic anemia, ulcerative colitis, Crohn's disease, or uveitis in a subject in need thereof, comprising administering to the subject an effective amount of a compound represented by structural formula (V):

or a pharmaceutically acceptable salt thereof, wherein:

each Z is independently selected from the group consisting of a lower alkyl, a lower haloalkyl, a halo, a lower alkoxy, a lower alkyl sulfanyl, cyano, nitro, and lower haloalkoxy;

R 12 is an aryl or a heteroaryl, wherein the aryl and heteroaryl are optionally substituted with one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, haloalkyl, aralkyl, heteraralkyl, a halo, cyano, nitro, —OR 17 , —SR 17 , —S(O) p R 17 , —S(O) p OR 17 , —OS(O) p R 17 , —OS(O) p OR 17 , —NR 17 S(O) p R 17 , —S(O) p NR 15 R 16 , —NR 15 R 16 , —C(X 3 )R 17 , —C(X 3 )OR 17 , —C(X 3 )SR 17 , —C(X 3 )NR 15 R 16 , —NR 17 C(X 3 )R 18 , —NR 17 C(X 3 )OR 18 , —NR 17 C(X 3 )SR 18 , —NR 17 C(X 3 )NR 15 R 16 , —OC(X 3 )R 17 , —OC(X 3 )OR 17 , —OC(X 3 )SR 17 , —SC(X 3 )OR 17 , —SC(X 3 )SR 17 , —OC(X 3 )NR 15 R 16 , —SC(X 3 )NR 15 R 16 , —P(X 4 )(X 5 R 17 ) 2 , —X 5 P(X 4 )(X 5 R 17 ) 2 , —P(X 4 )(R 17 ) 2 , and —P(X 4 )(R 17 )(X 5 R 17 );

R 13 is a cycloalkyl, a cycloalkenyl, an aryl, or a heteroaryl, wherein the cycloalkyl, cycloalkenyl, aryl, or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of a lower alkyl, a halo, cyano, nitro, a lower haloalkyl, a lower alkoxy, a lower sulfanylalkyl, —S(O) p R 31 , —S(O) p NR 29 R 30 , —NR 29 R 30 , —C(O)R 28 , —C(O)OR 28 , —C(O)NR 29 R 30 , —NR 29 C(O)R 30 , —NR 29 C(O)OR 28 , —NR 28 C(O)NR 29 R 30 , —OC(O)R 28 , —OC(O)OR 28 , and —OC(O)NR 29 R 30 ; wherein R 28 , R 29 , R 30 , for each occurrence are, independently, H or a lower alkyl; and R 31 , for each occurrence, is independently a lower alkyl;

R 14 , for each occurrence is independently —H, an alkyl, —C(O)R 20 , or —C(O)OR 20 ;

R 15 and R 16 , for each occurrence are, independently, H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, aralkyl, or heteraralkyl; or R 15 and R 16 are taken together with the nitrogen to which they are attached to form heterocyclyl or heteroaryl;

R 17 and R 18 , for each occurrence are, independently, H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, aralkyl, or heteraralkyl;

R 19 , for each occurrence, is independently —H, a halo, an alkyl, —OR 17 , —NR 15 R 16 , —C(O)R 17 , —C(O)OR 17 , or —C(O)NR 15 R 16 ;

R 20 , for each occurrence, is independently, H or an alkyl;

X 3 is ═O, ═S, or ═N—R 19 ;

X 4 is ═O or ═S;

X 5 is —O— or —S—;

n is 0, 1 or 2; and

p is 1 or 2.

2. The method of claim 1 , wherein R 12 is selected from the group consisting of phenyl, naphthyl, anthracenyl, pyridyl, furyl, thienyl, pyrrolyl, oxazolyl, imidazolyl, indolizinyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, triazolyl, thiadiazolyl, quinolinyl, isoquinolinyl, indazolyl, benzofuryl, imidazopyridinyl, tetrazolyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, benzoxadiazolyl, indolyl, azaindolyl, quinazolinyl, purinyl, pyrrolo[2,3]pyrimidyl, pyridopyrimidyl, pyrazolo[3,4]pyrimidyl, and benzo(b)thienyl.

3. The method of claim 2 , wherein R 12 is phenyl, tetrazolyl, or pyridinyl.

4. The method of claim 1 , wherein R 13 is aryl or heteroaryl.

5. The method of claim 4 , wherein R 13 is phenyl or pyridinyl.

6. The method of claim 5 , wherein the compound is of formula (III):

or a pharmaceutically acceptable salt thereof, wherein:

X 1 is CH, CR 4 , or N;

X 2 is CH, CR 3 , or N;

R 3 , for each occurrence, is, independently, a halo, cyano, nitro, a lower alkyl, a lower haloalkyl, a lower alkoxy, a lower alkylsulfanyl, —NH 2 , a lower alkylamino, a lower dialkylamino, or —C(O)R a , where R a is H or lower alkyl;

R 4 , for each occurrence, is, independently, a halo, cyano, nitro, an alkyl, an alkoxy, alkylsulfanyl, hydroxyl, a heteroaryl, —NH 2 , alkylamino, dialkylamino, or —C(O)R 6 ;

R 6 , for each occurrence, is independently, H, an alkyl, a cycloalkyl, a heterocyclyl, an aryl, a heteroaryl, an aralkyl, a heteraralkyl, —OR 7 , —SR 7 , or —NR 7 R 7 ;

R 7 , for each occurrence, is independently, H, an alkyl, a cycloalkyl, a heterocyclyl, an aryl, a heteroaryl, an aralkyl, or a heteraralkyl; and

q and t, for each occurrence are, independently, 0 or an integer from 1 to 4, inclusive.

7. The method of claim 6 , wherein the compound is of formula (IV):

or a pharmaceutically acceptable salt thereof, wherein:

X 6 and X 7 are each, independently, CH or N;

R 8 and R 9 are each, independently, a halo, a lower alkyl, a lower alkoxy, or a lower haloalkyl; and

R 10 and R 11 , are each, independently, a halo, cyano, a lower alkyl, a lower alkoxy, a lower alkyl ester, —C(O)NH 2 , furanyl, oxazolyl, oxadiazolyl, or tetrazolyl.

8. The method of claim 7 , wherein R 8 and R 9 are fluoro.

9. The method of claim 1 , wherein the compound is selected from the group consisting of:

N-[5-(2-Chloro-5-trifluoromethyl-phenyl)-pyrazin-2-yl]-2,6-difluoro-benzamide;

N-[5-(2-Chloro-5-trifluoromethyl-phenyl)-pyrazin-2-yl]-3-fluoro-isonicotinamide;

N-[5-(2-Chloro-5-trifluoromethyl-phenyl)-pyrazin-2-yl]-3-methyl-isonicotinamide;

N-[5-(2-Chloro-5-trifluoromethyl-phenyl)-pyrazin-2-yl]-2,6-difluoro-benzamide hydrochloride;

2,6-Difluoro-N-{5-[2-methyl-5-(1-methyl-1H-tetrazol-5-yl)-phenyl]-pyrazin-2-yl}-benzamide;

3-[5-(2,6-Difluoro-benzoylamino)-pyrazin-2-yl]-4-methyl-benzoic acid methyl ester;

4-Methyl-3-{5-[(3-methyl-pyridine-4-carbonyl)-amino]-pyrazin-2-yl}-benzoic acid methyl ester;

3-[5-(2,6-Difluoro-benzoylamino)-pyrazin-2-yl]-4-methyl-benzoic acid propyl ester;

3-[5-(2,6-Difluoro-benzoylamino)-pyrazin-2-yl]-4-methyl-benzoic acid 2-methoxy-ethyl ester;

4-Chloro-3-[5-(2,6-difluoro-benzoylamino)-pyrazin-2-yl]-benzoic acid methyl ester;

4-Chloro-3-[5-(2,6-difluoro-benzoylamino)-pyrazin-2-yl]-benzoic acid ethyl ester;

4-Chloro-3-[5-(2,6-difluoro-benzoylamino)-pyrazin-2-yl]-benzoic acid 2-methoxy-ethyl ester;

2,6-Difluoro-N-[5-(5-furan-2-yl-2-methoxy-pyridin-3-yl)-pyrazin-2-yl]-benzamide;

2,6-Difluoro-N-[5-(5-furan-3-yl-2-methoxy-pyridin-3-yl)-pyrazin-2-yl]-benzamide;

N-[5-(5-Chloro-2-methoxy-pyridin-3-yl)-pyrazin-2-yl]-2,6-difluoro-benzamide;

N-[5-(5-Bromo-2-methoxy-pyridin-3-yl)-pyrazin-2-yl]-2,6-difluoro-benzamide;

N-[5-(2-Ethyl-5-trifluoromethyl-phenyl)-pyrazin-2-yl]-2,6-difluoro-benzamide;

3-[5-(2,6-Difluoro-benzoylamino)-pyrazin-2-yl]-4-methyl-benzamide;

4-[5-(2,6-Difluoro-benzoylamino)-pyrazin-2-yl]-3-methyl-benzoic acid methyl ester;

4-[5-(2,6-Difluoro-benzoylamino)-pyrazin-2-yl]-3-methyl-benzoic acid ethyl ester;

4-[5-(2,6-Difluoro-benzoylamino)-pyrazin-2-yl]-3-methyl-benzoic acid 2-methoxy-ethyl ester;

3-Chloro-4-[5-(2,6-difluoro-benzoylamino)-pyrazin-2-yl]-benzoic acid methyl ester;

3-Chloro-4-[5-(2,6-difluoro-benzoylamino)-pyrazin-2-yl]-benzoic acid ethyl ester;

3-Chloro-4-[5-(2,6-difluoro-benzoylamino)-pyrazin-2-yl]-benzoic acid 2-methoxy-ethyl ester;

3-Fluoro-N-[5-(5-furan-2-yl-2-methoxy-pyridin-3-yl)-pyrazin-2-yl]-isonicotinamide;

3-Fluoro-N-[5-(5-furan-3-yl-2-methoxy-pyridin-3-yl)-pyrazin-2-yl]-isonicotinamide;

N-[5-(5-Chloro-2-methoxy-pyridin-3-yl)-pyrazin-2-yl]-3-fluoro-isonicotinamide;

N-[5-(5-Bromo-2-methoxy-pyridin-3-yl)-pyrazin-2-yl]-3-fluoro-isonicotinamide;

3-Fluoro-N-[5-(2-methyl-5-trifluoromethyl-phenyl)-pyrazin-2-yl]-isonicotinamide;

N-[5-(5-Carbamoyl-2-methyl-phenyl)-pyrazin-2-yl]-3-fluoro-isonicotinamide;

N-[5-(5-Cyano-2-methyl-phenyl)-pyrazin-2-yl]-3-fluoro-isonicotinamide;

3-{5-[(3,5-Difluoro-pyridine-4-carbonyl)-amino]-pyrazin-2-yl}-4-methyl-benzoic acid methyl ester;

3-{5-[(3,5-Difluoro-pyridine-4-carbonyl)-amino]-pyrazin-2-yl}-4-methyl-benzoic acid ethyl ester;

3-{5-[(3,5-Difluoro-pyridine-4-carbonyl)-amino]-pyrazin-2-yl}-4-methyl-benzoic acid 2-methoxy-ethyl ester;

4-Chloro-3-{5-[(3,5-difluoro-pyridine-4-carbonyl)-amino]-pyrazin-2-yl}-benzoic acid methyl ester;

4-Chloro-3-{5-[(3,5-difluoro-pyridine-4-carbonyl)-amino]-pyrazin-2-yl}-benzoic acid ethyl ester;

4-Chloro-3-{5-[(3,5-difluoro-pyridine-4-carbonyl)-amino]-pyrazin-2-yl}-benzoic acid 2-methoxy-ethyl ester;

3,5-Difluoro-N-[5-(5-furan-2-yl-2-methoxy-pyridin-3-yl)-pyrazin-2-yl]-isonicotinamide;

3,5-Difluoro-N-[5-(5-furan-3-yl-2-methoxy-pyridin-3-yl)-pyrazin-2-yl]-isonicotinamide;

N-[5-(5-Chloro-2-methoxy-pyridin-3-yl)-pyrazin-2-yl]-3,5-difluoro-isonicotinamide;

N-[5-(5-Bromo-2-methoxy-pyridin-3-yl)-pyrazin-2-yl]-3,5-difluoro-isonicotinamide;

N-[5-(2-Ethyl-5-trifluoromethyl-phenyl)-pyrazin-2-yl]-3,5-difluoro-isonicotinamide;

N-[5-(5-Carbamoyl-2-methyl-phenyl)-pyrazin-2-yl]-3,5-difluoro-isonicotinamide;

3,5-Difluoro-N-[5-(5-cyano-2-methyl-phenyl)-pyrazin-2-yl]-isonicotinamide;

4-Methyl-3-{5-[(3-methyl-pyridine-4-carbonyl)-amino]-pyrazin-2-yl}-benzoic acid ethyl ester;

4-Methyl-3-{5-[(3-methyl-pyridine-4-carbonyl)-amino]-pyrazin-2-yl}-benzoic acid 2-methoxy-ethyl ester;

4-Chloro-3-{5-[(3-methyl-pyridine-4-carbonyl)-amino]-pyrazin-2-yl}-benzoic acid methyl ester;

4-Chloro-3-{5-[(3-methyl-pyridine-4-carbonyl)-amino]-pyrazin-2-yl}-benzoic acid ethyl ester;

4-Chloro-3-{5-[(3-methyl-pyridine-4-carbonyl)-amino]-pyrazin-2-yl}-benzoic acid 2-methoxy-ethyl ester;

N-[5-(2-Chloro-5-furan-2-yl-phenyl)-pyrazin-2-yl]-3-methyl-isonicotinamide;

N-[5-(2-Chloro-5-furan-3-yl-phenyl)-pyrazin-2-yl]-3-methyl-isonicotinamide;

N-[5-(5-Chloro-2-methoxy-pyridin-3-yl)-pyrazin-2-yl]-3-methyl-isonicotinamide;

N-[5-(5-Bromo-2-methoxy-pyridin-3-yl)-pyrazin-2-yl]-3-methyl-isonicotinamide;

N-[5-(2-Ethyl-5-trifluoromethyl-phenyl)-pyrazin-2-yl]-3-methyl-isonicotinamide;

N-[5-(5-Carbamoyl-2-methyl-phenyl)-pyrazin-2-yl]-3-methyl-isonicotinamide;

N-[5-(5-Cyano-2-methyl-phenyl)-pyrazin-2-yl]-3-methyl-isonicotinamide;

2,6-Difluoro-N-[5-(2-methyl-5-oxazol-2-yl-phenyl)-pyrazin-2-yl]-benzamide;

2,6-Difluoro-N-{5-[2-methyl-5-(3-methyl-[1,2,4]oxadiazol-5-yl)-phenyl]-pyrazin-2-yl}-benzamide;

2,6-Difluoro-N-{5-[2-methyl-5-(1H-tetrazol-5-yl)-phenyl]-pyrazin-2-yl}-benzamide;

3-Fluoro-N-[5-(2-methyl-5-oxazol-2-yl-phenyl)-pyrazin-2-yl]-isonicotinamide;

3-Methyl-N-[5-(2-methyl-5-oxazol-2-yl-phenyl)-pyrazin-2-yl]-isonicotinamide;

3,5-Difluoro-N-[5-(2-methyl-5-oxazol-2-yl-phenyl)-pyrazin-2-yl]-isonicotinamide;

4-Methyl-[1,2,3]thiadiazole-5-carboxylic acid [5-(2-methyl-5-oxazol-2-yl-phenyl)-pyrazin-2-yl]-amide;

3-Fluoro-N-[5-(2-methyl-5-thiazol-2-yl-phenyl)-pyrazin-2-yl]-isonicotinamide;

3-Methyl-N-[5-(2-methyl-5-thiazol-2-yl-phenyl)-pyrazin-2-yl]-isonicotinamide;

3,5-Difluoro-N-[5-(2-methyl-5-thiazol-2-yl-phenyl)-pyrazin-2-yl]-isonicotinamide;

4-Methyl-[1,2,3]thiadiazole-5-carboxylic acid [5-(2-methyl-5-thiazol-2-yl-phenyl)-pyrazin-2-yl]-amide;

N-[5-(2-Chloro-5-oxazol-2-yl-phenyl)-pyrazin-2-yl]-3-fluoro-isonicotinamide;

N-[5-(2-Chloro-5-oxazol-2-yl-phenyl)-pyrazin-2-yl]-3-methyl-isonicotinamide;

N-[5-(2-Chloro-5-oxazol-2-yl-phenyl)-pyrazin-2-yl]-3,5-difluoro-isonicotinamide;

4-Methyl-[1,2,3]thiadiazole-5-carboxylic acid [5-(2-chloro-5-oxazol-2-yl-phenyl)-pyrazin-2-yl]-amide;

3-Fluoro-N-[5-(2-methyl-5-[1,3,4]oxadiazol-2-yl-phenyl)-pyrazin-2-yl]-isonicotinamide;

3-Methyl-N-[5-(2-methyl-5-[1,3,4]oxadiazol-2-yl-phenyl)-pyrazin-2-yl]-isonicotinamide;

3,5-Difluoro-N-[5-(2-methyl-5-[1,3,4]oxadiazol-2-yl-phenyl)-pyrazin-2-yl]-isonicotinamide;

4-Methyl-[1,2,3]thiadiazole-5-carboxylic acid [5-(2-methyl-5-[1,3,4]oxadiazol-2-yl-phenyl)-pyrazin-2-yl]-amide;

3-Fluoro-N-[5-(2-methyl-5-[1,3,4]thiadiazol-2-yl-phenyl)-pyrazin-2-yl]-isonicotinamide;

3-Methyl-N-[5-(2-methyl-5-[1,3,4]thiadiazol-2-yl-phenyl)-pyrazin-2-yl]-isonicotinamide;

3,5-Difluoro-N-[5-(2-methyl-5-[1,3,4]thiadiazol-2-yl-phenyl)-pyrazin-2-yl]-isonicotinamide;

4-Methyl-[1,2,3]thiadiazole-5-carboxylic acid [5-(2-methyl-5-[1,3,4]thiadiazol-2-yl-phenyl)-pyrazin-2-yl]-amide;

N-[5-(2-Chloro-5-[1,3,4]oxadiazol-2-yl-phenyl)-pyrazin-2-yl]-3-fluoro-isonicotinamide;

N-[5-(2-Chloro-5-[1,3,4]oxadiazol-2-yl-phenyl)-pyrazin-2-yl]-3-methyl-isonicotinamide;

N-[5-(2-Chloro-5-[1,3,4]oxadiazol-2-yl-phenyl)-pyrazin-2-yl]-3,5-difluoro-isonicotinamide;

4-Methyl-[1,2,3]thiadiazole-5-carboxylic acid [5-(2-chloro-5-[1,3,4]oxadiazol-2-yl-phenyl)-pyrazin-2-yl]-amide;

3-Fluoro-N-[5-(2-methyl-5-oxazol-5-yl-phenyl)-pyrazin-2-yl]-isonicotinamide;

3-Methyl-N-[5-(2-methyl-5-oxazol-5-yl-phenyl)-pyrazin-2-yl]-isonicotinamide;

3,5-Difluoro-N-[5-(2-methyl-5-oxazol-5-yl-phenyl)-pyrazin-2-yl]-isonicotinamide;

4-Methyl-[1,2,3]thiadiazole-5-carboxylic acid [5-(2-methyl-5-oxazol-5-yl-phenyl)-pyrazin-2-yl]-amide;

3-Fluoro-N-[5-(2-methyl-5-thiazol-5-yl-phenyl)-pyrazin-2-yl]-isonicotinamide;

3-Methyl-N-[5-(2-methyl-5-thiazol-5-yl-phenyl)-pyrazin-2-yl]-isonicotinamide;

3,5-Difluoro-N-[5-(2-methyl-5-thiazol-5-yl-phenyl)-pyrazin-2-yl]-isonicotinamide;

4-Methyl-[1,2,3]thiadiazole-5-carboxylic acid [5-(2-methyl-5-thiazol-5-yl-phenyl)-pyrazin-2-yl]-amide;

N-[5-(2-Chloro-5-oxazol-5-yl-phenyl)-pyrazin-2-yl]-3-fluoro-isonicotinamide;

N-[5-(2-Chloro-5-oxazol-5-yl-phenyl)-pyrazin-2-yl]-3-methyl-isonicotinamide;

N-[5-(2-Chloro-5-oxazol-5-yl-phenyl)-pyrazin-2-yl]-3,5-difluoro-isonicotinamide;

4-Methyl-[1,2,3]thiadiazole-5-carboxylic acid [5-(2-chloro-5-oxazol-5-yl-phenyl)-pyrazin-2-yl]-amide;

3-Fluoro-N-[5-(5-isoxazol-5-yl-2-methyl-phenyl)-pyrazin-2-yl]-isonicotinamide;

N-[5-(5-Isoxazol-5-yl-2-methyl-phenyl)-pyrazin-2-yl]-3-methyl-isonicotinamide;

3,5-Difluoro-N-[5-(5-isoxazol-5-yl-2-methyl-phenyl)-pyrazin-2-yl]-isonicotinamide;

4-Methyl-[1,2,3]thiadiazole-5-carboxylic acid [5-(5-isoxazol-5-yl-2-methyl-phenyl)-pyrazin-2-yl]-amide;

3-Fluoro-N-[5-(5-isothiazol-5-yl-2-methyl-phenyl)-pyrazin-2-yl]-isonicotinamide;

N-[5-(5-Isothiazol-5-yl-2-methyl-phenyl)-pyrazin-2-yl]-3-methyl-isonicotinamide;

3,5-Difluoro-N-[5-(5-isothiazol-5-yl-2-methyl-phenyl)-pyrazin-2-yl]-isonicotinamide;

4-Methyl-[1,2,3]thiadiazole-5-carboxylic acid [5-(5-isothiazol-5-yl-2-methyl-phenyl)-pyrazin-2-yl]-amide;

N-[5-(2-Chloro-5-isoxazol-5-yl-phenyl)-pyrazin-2-yl]-3-fluoro-isonicotinamide;

N-[5-(2-Chloro-5-isoxazol-5-yl-phenyl)-pyrazin-2-yl]-3-methyl-isonicotinamide;

N-[5-(2-Chloro-5-isoxazol-5-yl-phenyl)-pyrazin-2-yl]-3,5-difluoro-isonicotinamide;

4-Methyl-[1,2,3]thiadiazole-5-carboxylic acid [5-(2-chloro-5-isoxazol-5-yl-phenyl)-pyrazin-2-yl]-amide;

3-{5-[(3-Fluoro-pyridine-4-carbonyl)-amino]-pyrazin-2yl}-4-methyl-benzoic acid methyl ester;

N-[5-(2,5-Dimethoxy-phenyl)-pyrazin-2-yl]-2,6-difluoro-benzamide;

N-[5-(2-Chloro-5-trifluoromethyl-phenyl)-pyrazin-2-yl]-2-methyl-nicotinamide;

Cyclohexanecarboxylic acid [5-(2-chloro-5-trifluoromethyl-phenyl)-pyrazin-2-yl]amide;

N-[5-(2,5-Dimethoxy-phenyl)-pyrazin-2-yl]-3-fluoro-isonicotinamide;

4-Methyl-[1,2,3]thiadiazole-5-carboxylic acid [5-(2-chloro-5-trifluoromethyl-phenyl)-pyrazin-2-yl]-amide;

N-[5-(2-Chloro-5-trifluoromethyl-phenyl)-pyrazin-2-yl]-3,5-difluoro-isonicotinamide;

N-[5-(2,5-Dimethoxy-phenyl)-pyrazin-2-yl]-3-methyl-isonicotinamide;

N-[5-(2,5-Dimethoxy-phenyl)-pyrazin-2-yl]-3,5-difluoro-isonicotinamide;

4-Methyl-[1,2,3]thiadiazole-5-carboxylic acid [5-(2,5-dimethoxy-phenyl)-pyrazin-2-yl]-amide;

Cyclohexanecarboxylic acid [5-(2,5-dimethoxy-phenyl)-pyrazin-2-yl]-amide; and

Cyclohexanecarboxylic acid [5-(2-methyl-5-oxazol-2-yl-phenyl)-pyrazin-2-yl]-amide;

or a pharmaceutically acceptable salt thereof.

10. The method of claim 1 , or a pharmaceutically acceptable salt thereof, wherein

R 12 is phenyl or pyridinyl optionally substituted with one or more substituents selected from the group consisting of alkyl, haloalkyl, heteroaryl, a halo, cyano, —OR 17 , —C(X3)OR 17 , and —C(X3)NR 15 R 16 .

11. The method of claim 1 , or a pharmaceutically acceptable salt thereof, wherein

R 13 is phenyl, pyridinyl, [1,2,3]-thiadiazole or cyclohexyl, each of which is optionally substituted with one or more substituents selected from the group consisting of a lower alkyl, a halo, cyano, a lower haloalkyl, and a lower alkoxy.

12. The method of claim 1 , or a pharmaceutically acceptable salt thereof, wherein

R 14 is H.

13. The method of claim 1 , or a pharmaceutically acceptable salt thereof, wherein n is 0.

14. The method of claim 1 , or a pharmaceutically acceptable salt thereof, wherein

R 15 and R 16 , for each occurrence are, independently, H, alkyl, or R 15 and R 16 are taken together with the nitrogen to which they are attached to form heterocyclyl or heteroaryl.

15. The method of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 17 is H, alkyl, or cycloalkyl.

16. The method of claim 1 , or a pharmaceutically acceptable salt thereof, wherein

R 12 is phenyl or pyridinyl optionally substituted with one or more substituents selected from the group consisting of alkyl, haloalkyl, heteroaryl, a halo, cyano, —OR 17 , —C(X3)OR 17 , and —C(X3)NR 15 R 16 ;

R 13 is phenyl, pyridinyl, [1,2,3]-thiadiazole or cyclohexyl, each of which is optionally substituted with one or more substituents selected from the group consisting of a lower alkyl, a halo, cyano, a lower haloalkyl, and a lower alkoxy;

R 14 is H;

R 15 and R 16 , for each occurrence are, independently, H, alkyl, or R 15 and R 16 are taken together with the nitrogen to which they are attached to form heterocyclyl or heteroaryl;

R 17 is H, alkyl or cycloalkyl;

X 3 is ═O; and

n is 0.

17. The method of claim 16 , or a pharmaceutically acceptable salt thereof, wherein

R 12 is phenyl or pyridinyl optionally substituted with one or more substituents selected from the group consisting of alkyl of 1 to 4 carbon atoms, haloalkyl of 1 to 4 carbon atoms, monocyclic 5- or 6-membered heteroaryl comprising 1 or 2 heteroatoms selected from O and N, cyano, a halo selected from fluoro and chloro, —OR 17 , —C(X 3 )OR 17 , and —C(X 3 )NR 15 R 16 ;

R 13 is phenyl or pyridinyl, each of which is optionally substituted with one or more substituents selected from the group consisting of an alkyl of 1 to 4 carbon atoms and a fluoro atom;

R 14 is H;

R 15 and R 16 are H;

R 17 is H, an alkyl of 1 to 4 carbon atoms or cycloalkyl;

X 3 is ═O; and

n is 0.

18. The method of claim 17 , or a pharmaceutically acceptable salt thereof, wherein

R 12 is phenyl, optionally substituted with one or more substituents selected from the group consisting of —CH 3 , —CF 3 , chloro, cyano, monocyclic 5-membered heteroaryl comprising 1 or 2 heteroatoms selected from O and N, —OR 17 , —C(O)OR 17 , and —C(O)NH 2 ;

R 13 is pyridinyl, which is optionally substituted with one or more substituents selected from the group consisting of an alkyl of 1 to 4 carbon atoms and a fluoro atom; and

R 17 is alkyl of 1 to 4 carbon atoms or cycloalkyl.

19. The method of claim 18 for treating organ transplant rejection.

20. The method of claim 18 for treating psoriasis.

21. The method of claim 18 for treating rheumatoid arthritis.

22. The method of claim 18 for treating ulcerative colitis.

23. The method of claim 18 for treating Crohn's disease.